The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use

Emerging Health Threats Journal

Volumn 4, Issue 1, 2011, Pages

  Kalsi, Sarbjeet S ^a   Wood, David M ^a,b   Dargan, Paul I ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

2 (2 chlorophenyl) 2 (methylamino) cyclohexanone; Acute toxicity; Chronic toxicity; Dependence; Epidemiology; Haemorrhagic cystitis; Ketamine; Recreational drugs

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BENZODIAZEPINE DERIVATIVE; CENTRAL DEPRESSANT AGENT; KETAMINE;

ABDOMINAL PAIN; ACUTE TOXICITY; AGITATION; ANALGESIC ACTIVITY; ANXIETY; CHRONIC TOXICITY; CLINICAL FEATURE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG MISUSE; DRUG POTENCY; DRUG TOLERANCE; GASTROINTESTINAL TOXICITY; GEOGRAPHIC DISTRIBUTION; HALLUCINATION; HEART PALPITATION; HEMORRHAGIC CYSTITIS; HUMAN; HYPERTENSION; LETHAL DOSE; LIVER FUNCTION TEST; LUNG EDEMA; MENTAL DISEASE; NEUROTOXICITY; NONHUMAN; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEX DIFFERENCE; TACHYCARDIA; THORAX PAIN; URINARY TRACT DISEASE;

EID: 80052744525     PISSN: 17528550     EISSN: 17528550     Source Type: Journal    
DOI: 10.3402/ehtj.v4i0.7107     Document Type: Review

References (105)

1. Domino EF, Chodoff P, Corssen G. Pharmacologic effects of Ci-581, a new dissociative anesthetic, in man. Clin Pharmacol Ther. 1965;6:279-91.
2. WHO. WHO model list of essential medications. 16th ed. Geneva: Author; 2010.
3. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;182:313-33.
4. Noppers I, Niesters M, Aarts L, Smith T, Sarton E, Dahan A. Ketamine for the treatment of chronic non-cancer pain. Expert Opin Pharmacother. 2010;11:2417-29.
5. Jansen KLR. Ketamine: Dreams and realities. 2nd ed. Sarasota, FL: Multidisciplinary Association for Psychedelic Studies; 2004.
6. White PF, Schuttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. Comparative pharmacology of the ketamine isomers. Studies in volunteers. Br J Anaesth. 1985;57:197-203.
7. Jansen KL. A review of the nonmedical use of ketamine: Use, users and consequences. J Psychoactive Drugs. 2000;32:419-33.
8. EMCDDA. Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs. Luxembourg: Office for Official Publications of the European Communities; 2002.
9. Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. 1982;71:539-42.
10. Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth. 1996;77:203-7.
11. Cohen ML, Trevor AJ. On the cerebral accumulation of ketamine and the relationship between metabolism of the drug and its pharmacological effects. J Pharmacol Exp Ther. 1974;189:351-8.
12. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853-8.
13. Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist. 1975;24:260-3.
14. Parkin MC, Turfus SC, Smith NW, Halket JM, Braithwaite RA, Elliott SP, et al. Detection of ketamine and its metabolites in urine by ultra high pressure liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876:137-42.
15. Adamowicz P, Kala M. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: Method and detection window considerations. J Anal Toxicol. 2005;29:376-82.
16. Irifune M, Shimizu T, Nomoto M, Fukuda T. Ketamineinduced anesthesia involves the N-methyl-D-aspartate receptor-channel complex in mice. Brain Res. 1992;596:1-9.
17. Zeilhofer HU, Swandulla D, Geisslinger G, Brune K. Differential effects of ketamine enantiomers on NMDA receptor currents in cultured neurons. Eur J Pharmacol. 1992;213: 155-8.
18. Bergman SA. Ketamine: Review of its pharmacology and its use in pediatric anesthesia. Anesth Prog. 1999;46:10-20.
19. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE. Oral ketamine is antinociceptive in the rat formalin test: Role of the metabolite, norketamine. Pain. 1999;81:85-93.
20. Smith DJ, Pekoe GM, Martin LL, Coalgate B. The interaction of ketamine with the opiate receptor. Life Sci. 1980;26:789-95.
21. Bevan RK, Rose MA, Duggan KA. Evidence for direct interaction of ketamine with alpha 1- and beta 2-adrenoceptors. Clin Exp Pharmacol Physiol. 1997;24:923-26.
22. Lundy PM, Lockwood PA, Thompson G, Frew R. Differential effects of ketamine isomers on neuronal and extraneuronal catecholamine uptake mechanisms. Anesthesiology. 1986;64: 359-63.
23. Durieux ME. Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg. 1995;81:57-62.
24. Cohen MG, Chan SL, Bhargava HN, Trevor AJ. Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochem Pharmacol. 1974;23:1647-52.
25. Sato T, Matsuki A, Zsigmond EK, Rabito SF. Ketamine relaxes airway smooth muscle contracted by endothelin. Anesth Analg. 1997;84:900-6.
26. Lindefors N, Barati S, O'Connor WT. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. Brain Res. 1997;759:205-12.
27. Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methylaspartate. Br J Pharmacol. 1983;79:565-75.
28. Irifune M, Sato T, Kamata Y, Nishikawa T, Dohi T, Kawahara M. Evidence for GABA(A) receptor agonistic properties of ketamine: Convulsive and anesthetic behavioral models in mice. Anesth Analg. 2000;91:230-6.
29. FDA. Ketamine abuse. FDA Drug Bull. 1979;9:24.
30. Laidler KAJ. The rise of club drugs in a heroin society: The case of Hong Kong. Subst Use Misuse. 2005;40:1257-78.
31. AIHW (Australian Institute of Health and Welfare). 2007 National drug survey household survey: Detailed findings. Canberra: Author; 2008.
32. Paglia-Boak A, Mann RE, Adlaf EM, Rehm J. Drug use among Ontario students, 1977-2009: Detailed OSDUHS findings. Toronto, Ontario: Centre for Addiction and Mental Health; 2009.
33. Hoare J, Moon D. Drug misuse declared: Findings from the 2009/10 British crime survey England and Wales. Home Office Statistical Bulletin. London: Home Office; 2010, p. 1-109.
34. SAMSHA (Substance Abuse and Mental Health Services Administration). The NSDUH report: Use of specific hallucinogens 2006. Rockville, MD: Author; 2008.
35. Barrett SP, Gross SR, Garand I, Pihl RO. Patterns of simultaneous polysubstance use in Canadian rave attendees. Subst Use Misuse. 2005;40:1525-37.
36. EMCDDA. Annual Report 2006. Selected Issue 3: Developments in drug use within recreational settings. Luxembourg: Office for Official Publications of the European Communities; 2006.
37. Dick D, Torrance C. Mixmag drugs survey. Mixmag (The world's biggest dance music and clubbing magazine). 2010 February, p. 44-53.
38. Lua AC, Lin HR, Tseng YT, Hu AR, Yeh PC. Profiles of urine samples from participants at rave party in Taiwan: Prevalence of ketamine and MDMA abuse. Forensic Sci Int. 2003;136: 47-51.
39. Dillon P, Copeland J, Jansen K. Patterns of use and harms associated with non-medical ketamine use. Drug Alcohol Depend. 2003;69:23-8.
40. Fendrich M, Johnson TP. Editors' introduction to this special issue on club drug epidemiology. Subst Use Misuse. 2005; 40:1179-84.
41. UNODC. United Nations office on drugs and crime: World drug report 2010. Vienna: United Nations Publications; 2010.
42. APAIC. Regional trends: Ketamine. Asia & Pacific Amphetamine-Type Stimulants Information Centre; 2009 [accessed 2010 October 21]. Available from: http://www.apaic.org/index.php? option_com_content&view_article&id_122&Itemid-135.
43. Anonymous. Central registry of drug abuse: Selected drug abuse statistics [Government Statistics] Hong Kong: Narcotics Division, Security Bureau, The Government of the Hong Kong Special Administrative Region; 2010 [accessed 2010 November 5]. Available from: http://www.nd.gov.hk/statistics_list/doc/en/ t3.pdf.
44. Wood DM, Bishop CR, Greene SL, Dargan PI. Ketaminerelated toxicology presentations to the ED [abstract]. Clin Toxicol. 2008;46:630.
45. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
46. Jansen KL. Non-medical use of ketamine. BMJ. 1993;306: 601-2.
47. Scott-Ham M, Burton FC. Toxicological findings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med. 2005;12:175-86.
48. Du Mont J, Macdonald S, Rotbard N, Bainbridge D, Asllani E, Smith N, et al. Drug-facilitated sexual assault in Ontario, Canada: Toxicological and DNA findings. J Forensic Leg Med. 2010;17:333-8.
49. Cheng JY, Chan DT, Mok VK. An epidemiological study on alcohol/drugs related fatal traffic crash cases of deceased drivers in Hong Kong between 1996 and 2000. Forensic Sci Int. 2005;153:196-201.
50. Wong OF, Tsui KL, Lam TS, Sze NN,Wong SC, Lau FL, et al. Prevalence of drugged drivers among non-fatal driver casualties presenting to a trauma centre in Hong Kong. Hong Kong Med J. 2010;16:246-51.
51. Weiner AL, Vieira L, McKay CA, Bayer MJ. Ketamine abusers presenting to the emergency department: A case series. J Emerg Med. 2000;18:447-51.
52. Pandey CK, Mathur N, Singh N, Chandola HC. Fulminant pulmonary edema after intramuscular ketamine. Can J Anaesth. 2000;47:894-6.
53. Murphy JL Jr. Hypertension and pulmonary oedema associated with ketamine administration in a patient with a history of substance abuse. Can J Anaesth. 1993;40:160-4.
54. Tarnow J, Hess W. Pulmonary hypertension and pulmonary edema caused by intravenous ketamine. Anaesthesist. 1978; 27:486-7.
55. Berger MM, Pitzer B, Zugel S, Wieland CW, Vlaar AP, Schultz MJ, et al. Alveolar but not intravenous S-ketamine inhibits alveolar sodium transport and lung fluid clearance in rats. Anesth Analg. 2010;111:164-70.
56. Peyton SH, Couch AT, Bost RO. Tissue distribution of ketamine: Two case reports. J Anal Toxicol. 1988;12:268-9.
57. Moore KA, Kilbane EM, Jones R, Kunsman GW, Levine B, Smith M. Tissue distribution of ketamine in a mixed drug fatality. J Forensic Sci. 1997;42:1183-5.
58. Gill JR, Stajic M. Ketamine in non-hospital and hospital deaths in New York City. J Forensic Sci. 2000;45:655-8.
59. Lalonde BR, Wallage HR. Postmortem blood ketamine distribution in two fatalities. J Anal Toxicol. 2004;28:71-4.
60. Schifano F, Corkery J, Oyefeso A, Tonia T, Ghodse AH. Trapped in the 'K-hole': Overview of deaths associated with ketamine misuse in the UK (1993-2006). J Clin Psychopharmacol. 2008;28:114-6.
61. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: A review. Psychopharmacology (Berl). 2006;188:408-24.
62. Morgan CJ, Rossell SL, Pepper F, Smart J, Blackburn J, Brandner B, et al. Semantic priming after ketamine acutely in healthy volunteers and following chronic self-administration in substance users. Biol Psychiatry. 2006;59:265-72.
63. Morgan CJ, Perry EB, Cho HS, Krystal JH, D'Souza DC. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology (Berl). 2006;187:405-14.
64. Blagrove M, Morgan CJ, Curran HV, Bromley L, Brandner B. The incidence of unpleasant dreams after sub-anaesthetic ketamine. Psychopharmacology (Berl). 2009;203:109-20.
65. Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing: A comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction. 2009;104:77-87.
66. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: A 1-year longitudinal study. Addiction. 2010;105:121-33.
67. Freeman TP, Morgan CJ, Klaassen E, Das RK, Stefanovic A, Brandner B, et al. Superstitious conditioning as a model of delusion formation following chronic but not acute ketamine in humans. Psychopharmacology (Berl). 2009;206:563-73.
68. Jansen KL. Ketamine-Can chronic use impair memory? Int J Addict. 1990;25:133-9.
69. Narendran R, Frankle WG, Keefe R, Gil R, Martinez D, Slifstein M, et al. Altered prefrontal dopaminergic function in chronic recreational ketamine users. Am J Psychiatry. 2005; 162:2352-9.
70. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, et al. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science. 1999;283:70-4.
71. Beals JK, Carter LB, Jevtovic-Todorovic V. Neurotoxicity of nitrous oxide and ketamine is more severe in aged than in young rat brain. Ann NY Acad Sci. 2003;993:115.
72. Jevtovic-Todorovic V, Carter LB. The anesthetics nitrous oxide and ketamine are more neurotoxic to old than to young rat brain. Neurobiol Aging. 2005;26:947-56.
73. Jevtovic-Todorovic V, Benshoff N, Olney JW. Ketamine potentiates cerebrocortical damage induced by the common anaesthetic agent nitrous oxide in adult rats. Br J Pharmacol. 2000;130:1692-8.
74. Wang C, Sadovova N, Patterson TA, Zou X, Fu X, Hanig JP, et al. Protective effects of 7-nitroindazole on ketamine-induced neurotoxicity in rat forebrain culture. Neurotoxicology. 2008; 29:613-20.
75. Zou X, Patterson TA, Divine RL, Sadovova N, Zhang X, Hanig JP, et al. Prolonged exposure to ketamine increases neurodegeneration in the developing monkey brain. Int J Dev Neurosci. 2009;27:727-31.
76. Liao Y, Tang J, Ma M, Wu Z, Yang M, Wang X, et al. Frontal white matter abnormalities following chronic ketamine use: A diffusion tensor imaging study. Brain. 2010;133:2115-22.
77. WHO. International Classification of Diseases (ICD) 10. 2nd ed. Geneva: Author; 2007 [updated 2010 November 5]. Available from: http://apps.who.int/classifications/apps/icd/ icd10online/index.htm?gf10.htm_F192.
78. Jansen KL, Darracot-Cankovic R. The nonmedical use of ketamine, part two: A review of problem use and dependence. J Psychoactive Drugs. 2001;33:151-8.
79. Morgan CJ, Rees H, Curran HV. Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med. 2008;38: 1331-40.
80. Lu Y, France CP, Woods JH. Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: Cross-tolerance between PCP-like compounds and competitive NMDA antagonists. J Pharmacol Exp Ther. 1992;263:499-504.
81. Moreton JE, Meisch RA, Stark L, Thompson T. Ketamine self-administration by the rhesus monkey. J Pharmacol Exp Ther. 1977;203:303-9.
82. Nutt D, Lingford-Hughes A, Daglish M. Future directions in substance dependence research. J Neural Transm Suppl. 2003;64:95-103.
83. Marietta MP, White PF, Pudwill CR, Way WL, Trevor AJ. Biodisposition of ketamine in the rat: Self-induction of metabolism. J Pharmacol Exp Ther. 1976;196:536-44.
84. Chan WH, Sun WZ, Ueng TH. Induction of rat hepatic cytochrome P-450 by ketamine and its toxicological implications. J Toxicol Environ Health A. 2005;68:1581-97.
85. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K-hole: Phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95: 219-29.
86. Chu PS, Ma WK, Wong SC, Chu RW, Cheng CH, Wong S, et al. The destruction of the lower urinary tract by ketamine abuse: A new syndrome? BJU Int. 2008;102:1616-22.
87. Cottrell A, Warren K, Ayres R, Weinstock P, Kumar V, Gillatt D. The destruction of the lower urinary tract by ketamine abuse: A new syndrome? BJU Int. 2008;102:1178-9.
88. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamineassociated ulcerative cystitis: A new clinical entity. Urology. 2007;69:810-2.
89. Selby NM, Anderson J, Bungay P, Chesterton LJ, Kolhe NV. Obstructive nephropathy and kidney injury associated with ketamine abuse [case report]. Nephrology Dialysis Transplantation Plus. 2008;1:310-2.
90. Yeung LY, Rudd JA, Lam WP, Mak YT, Yew DT. Mice are prone to kidney pathology after prolonged ketamine addiction. Toxicol Lett. 2009;191:275-8.
91. Gregoire MC, MacLellan DL, Finley GA. A pediatric case of ketamine-associated cystitis. Urology. 2008;71:1232-3.
92. Storr TM, Quibell R. Can ketamine prescribed for pain cause damage to the urinary tract? Palliat Med. 2009;23:670-2.
93. Mason K, Cottrell AM, Corrigan AG, Gillatt DA, Mitchelmore AE. Ketamine-associated lower urinary tract destruction: A new radiological challenge. Clin Radiol. 2010;65:795-800.
94. Tsai TH, Cha TL, Lin CM, Tsao CW, Tang SH, Chuang FP, et al. Ketamine-associated bladder dysfunction. Int J Urol. 2009;16:826-9.
95. Oxley JD, Cottrell AM, Adams S, Gillatt D. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology. 2009;55: 705-8.
96. Shahani R, Stewart RJ. Reply to letter-to-the-editor, Re: Shahani R, Streutker C, Dickson B, et al: Ketamine-associated ulcerative cystitis: A new clinical entity. Urology. 2007;69: 810-2. Urology. 2008;71(5):987.
97. Kallestrup EB, Jorgensen SS, Nording J, Hald T. Treatment of interstitial cystitis with Cystistat: A hyaluronic acid product. Scan J Urol Nephrol. 2005;39:143-7.
98. Lavazzo C, Athanasiou S, Pitsouni E, Falgas ME. Hyaluronic acid: An effective alternative treatment of interstitial cystitis, recurrent urinary infections and haemorrhagic cystitis? Eur Urol. 2007;51:1534-40.
99. Daha LK, Riedl CR, Lazar D, Hohlbrugger C, Pfluger H. Do cytometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol. 2005;57: 393-7.
100. Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, et al. 'Street ketamine'-associated bladder dysfunction: A report of ten cases. Hong Kong Med J. 2007;13:311-3.
101. Poon TL, Wong KF, Chan MY, Fung KW, Chu SK, Man CW, et al. Upper gastrointestinal problems in inhalational ketamine abusers. J Dig Dis. 2010;11:106-10.
102. Kimura F, Hashimoto Y, Shimodate Y, Hashimoto H, Ishihara H, Matsuki A. Clinical study on total intravenous anesthesia with droperidol, fentanyl and ketamine-8. Hepatic and renal functions following prolonged surgical operation of over 10 hours [in Japanese]. Masui. 1991;40:1371-5.
103. Ng SH, Lee HK, Chan YC, Lau FL. Dilated common bile ducts in ketamine abusers. Hong Kong Med J. 2009;15:157.
104. Wong SW, Lee KF, Wong J, Ng WW, Cheung YS, Lai PB. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J. 2009;15:53-6.
105. Lee ST, Wu TT, Yu PY, Chen RM. Apoptotic insults to human HepG2 cells induced by S-(+)-ketamine occurs through activation of a Bax-mitochondria-caspase protease pathway. Br J Anaesth. 2009;102:80-9.